MONTPELLIER, France - Sensorion (EPA:ALSEN), a biotechnology company focused on treatments for hearing loss disorders, has announced the completion of patient recruitment for its Phase 2a clinical trial of SENS-401. This trial is designed to test the drug's efficacy in preserving residual hearing in adults undergoing cochlear implant surgery.
The trial has screened 33 patients, exceeding the target enrollment of at least 27 participants. The multicentric, randomized, controlled open-label study evaluates the presence of SENS-401 in the cochlea after oral administration twice daily for 7 days prior to cochlear implantation. Treatment continues for 42 days post-surgery. The study is conducted in collaboration with Cochlear Limited, a leader in implantable hearing devices.
Chief Medical Officer of Sensorion, Dr. Géraldine Honnet, expressed satisfaction with reaching this crucial milestone and thanked the patients and physicians for their commitment. She highlighted that preliminary efficacy data have been promising, bolstering confidence in SENS-401's potential for hearing loss prevention.
SENS-401, also known as Arazasetron, is an orally administered small molecule aimed at protecting inner ear tissue from damage that leads to hearing impairment. The drug is currently being tested for the prevention of residual hearing loss in patients scheduled for cochlear implantation and for preventing Cisplatin Induced Ototoxicity in another Phase 2 trial. It has received Orphan Drug Designation in Europe and the U.S. for different hearing loss conditions.
Sensorion's broader portfolio includes gene therapy programs targeting hereditary forms of deafness and other small molecule programs for hearing loss treatment and prevention. The company plans to publish the primary endpoint data from the SENS-401 trial in the first half of 2024.
The information reported is based on a press release statement from Sensorion.
InvestingPro Insights
As Sensorion (EPA:ALSEN) progresses with its clinical trials for SENS-401, investors and industry observers are closely monitoring the company's financial health and stock performance. According to real-time data from InvestingPro, Sensorion holds a market cap of $105.43 million USD, reflecting the biotech's position in the market. Despite not being profitable in the last twelve months, with an adjusted P/E ratio of -4.11, the company's revenue growth has been notable, at 21.55% over the same period. This suggests a growing interest in their treatments and potential for future profitability.
InvestingPro Tips indicate that while Sensorion is trading at a high Price / Book multiple of 9.68, the company has experienced a strong return over the last month, with a 21.4% increase in its stock price. This uptick is supported by a six-month price total return of 62.62%, which may catch the eye of growth-oriented investors. However, analysts remain cautious, as Sensorion is quickly burning through cash and does not pay a dividend to shareholders, a factor for those seeking income investments to consider.
For those interested in a deeper analysis, InvestingPro offers additional tips on Sensorion, which can be accessed through an InvestingPro+ subscription, now available at a special New Year sale with a discount of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription. With these tools at your disposal, you can make more informed decisions on whether Sensorion fits into your investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.